A marker的問題，透過圖書和論文來找解法和答案更準確安心。 我們找到下列必買單品、推薦清單和精選懶人包

KJV Large Print Ultrathin Reference Bible, British Tan Leathertouch, Black-Letter Edition, Indexed

為了解決A marker的問題，作者Holman Bible Publishers 這樣論述：

The KJV Large Print Thinline Bible is easy-to-carry and easy-to-read, featuring a large 10-point type and a thinline design that slips easily into a backpack, tote bag, or purse. Breakthroughs in typography and paper manufacturing contribute to a thinline Bible that combines readability, portabil

ity, and durability. FEATURES Pure Cambridge Edition of the KJV text Thinline design that is less than one inch thick Durable Smyth-sewn lay-flat binding Two-column verse-by-verse text format Topical page headings 10-point type size Words of Christ in red Gilded page edges Ribbon marker for easy re

ferencing between pages ＂Where to Turn＂ section with Scripture references for common life issues Presentation page for gift-giving Full-color maps The KJV Large Print Thinline Bible features the authorized Pure Cambridge Edition text of the King James Version (KJV) translation. The KJV is one of th

e best-selling translations of all time and captures the beauty and majesty of God’s Word for those who love the rich heritage and reverent language of this rendering of the Holy Bible.

A marker進入發燒排行的影片

An Integrated Approach For Uncovering Novel DNA Methylation Biomarkers For Non-small Cell Lung Carcinoma

為了解決A marker的問題，作者VAIBHAV KUMAR SUNKARIA 這樣論述：

Introduction - Lung cancer is one of primal and ubiquitous cause of cancer related fatalities in the world. Leading cause of these fatalities is non-small cell lung cancer (NSCLC) with a proportion of 85%. The major subtypes of NSCLC are Lung Adenocarcinoma (LUAD) and Lung Small Cell Carcinoma (LUS

C). Early-stage surgical detection and removal of tumor offers a favorable prognosis and better survival rates. However, a major portion of 75% subjects have stage III/IV at the time of diagnosis and despite advanced major developments in oncology survival rates remain poor. Carcinogens produce wide

spread DNA methylation changes within cells. These changes are characterized by globally hyper or hypo methylated regions around CpG islands, many of these changes occur early in tumorigenesis and are highly prevalent across a tumor type.Structure - This research work took advantage of publicly avai

lable methylation profiling resources and relevant comorbidities for lung cancer patients extracted from meta-analysis of scientific review and journal available at PubMed and CNKI search which were combined systematically to explore effective DNA methylation markers for NSCLC. We also tried to iden

tify common CpG loci between Caucasian, Black and Asian racial groups for identifying ubiquitous candidate genes thoroughly. Statistical analysis and GO ontology were also conducted to explore associated novel biomarkers. These novel findings could facilitate design of accurate diagnostic panel for

practical clinical relevance.Methodology - DNA methylation profiles were extracted from TCGA for 418 LUAD and 370 LUSC tissue samples from patients compared with 32 and 42 non-malignant ones respectively. Standard pipeline was conducted to discover significant differentially methylated sites as prim

ary biomarkers. Secondary biomarkers were extracted by incorporating genes associated with comorbidities from meta-analysis of research articles. Concordant candidates were utilized for NSCLC relevant biomarker candidates. Gene ontology annotations were used to calculate gene-pair distance matrix fo

r all candidate biomarkers. Clustering algorithms were utilized to categorize candidate genes into different functional groups using the gene distance matrix. There were 35 CpG loci identified by comparing TCGA training cohort with GEO testing cohort from these functional groups, and 4 gene-based pa

nel was devised after finding highly discriminatory diagnostic panel through combinatorial validation of each functional cluster.Results – To evaluate the gene panel for NSCLC, the methylation levels of SCT(Secritin), FOXD3(Forkhead Box D3), TRIM58(Tripartite Motif Containing 58) and TAC1(Tachikinin

1) were tested. Individually each gene showed significant methylation difference between LUAD and LUSC training cohort. Combined 4-gene panel AUC, sensitivity/specificity were evaluated with 0.9596, 90.43%/100% in LUAD; 0.949, 86.95%/98.21% in LUSC TCGA training cohort; 0.94, 85.92%/97.37 in GEO 66

836; 0.91,89.17%/100% in GEO 83842 smokers; 0.948, 91.67%/100% in GEO83842 non-smokers independent testing cohort. Our study validates SCT, FOXD3, TRIM58 and TAC1 based gene panel has great potential in early recognition of NSCLC undetermined lung nodules. The findings can yield universally accurate

and robust markers facilitating early diagnosis and rapid severity examination.

Viral and Antiviral Nanomaterials: Synthesis, Properties, Characterization, and Application

為了解決A marker的問題，作者 這樣論述：

Devarajan Thangadurai, PhD, is Assistant Professor at Karnatak University, Dharwad in India and did his postdoctoral research at the University of Madeira, Portugal, University of Delhi, India, and ICAR National Research Centre for Banana, India. He is the recipient of Best Young Scientist Award wit

h Gold Medal from Acharya Nagarjuna University, India, and the VGST-SMYSR Young Scientist Award of the Government of Karnataka, India. He has interest and expertise in the fields of biotechnology and nanotechnology for sustainable future. He has authored/edited more than twenty five books with inter

national publishers in USA, Canada, Switzerland and India. He has authored/coauthored 210 publications inclusive of journal articles, book chapters, books and invited presentations. He has extensively travelled to many universities and institutes in Africa, Europe and Asia for academic works, scient

ific meetings, and international collaborations. Saher Islam, PhD, is an HEC Scholar (Higher Education Commission) of the Islamic Republic of Pakistan at the University of Veterinary and Animal Sciences, Lahore, where she received her BS, MPhil and PhD in Molecular Biology, Biotechnology and Bioinfo

rmatics. She is IRSIP Scholar at Cornell University, New York and Visiting Scholar at West Virginia State University, West Virginia in USA. She has keen research interests in genetics, molecular biology, biotechnology, and bioinformatics pertaining to animal, dairy and food science, and has ample ha

nds on experience in molecular marker analysis, whole genome sequencing and RNA sequencing. She has visited USA, UK, Singapore, Germany, Italy and Russia for academic and scientific trainings, courses, and meetings. She is the recipient of 2016 Boehringer Ingelheim Fonds Travel Grant from European M

olecular Biology Laboratory, Germany. She is an author/coauthor of 50 publications including journal articles, book chapters, books and conference presentations. Charles Oluwaseun Adetunji, PhD, is presently the Ag. Director of Intellectual Properties and Technology Transfer; Chairman Committee on R

esearch Grant and Associate Professor of Microbiology and Biotechnology at EUI. He has won several scientific awards and grants from renowned academic bodies like Council of Scientific and Industrial Research (CSIR) India, and Department of Biotechnology (DBT) India, The World Academy of Science (TW

AS) Italy, Netherlands Fellowship Programme (NPF) Netherlands, The Agency for International Development Cooperation Israel, Royal Academy of Engineering UK among many others. He has filed several scientific patents on nanobiosurfactants, nanobiopesticdes and many more. He has published over 150 scie

ntific journals and conference proceedings in international and local refereed journals. His research interest includes microbiology, biotechnology, post-harvest management, and nanotechnology. He is an editorial board member of many international journals and serves as a reviewer to many double-bli

nd peer review journals of Elsevier, Springer, Taylor and Francis, Wiley, PLOS One, Nature, American Chemistry Society, Bentham Science Publishers etc. He is a member of many scientific and professional bodies like American Society for Microbiology, Nigerian Young Academy, Biotechnology Society of N

igeria, and Nigerian Society for Microbiology. He has won international recognition and also acted as a keynote speaker delivering invited talk/position paper at various universities, research institutes and several centers of excellence which span across several continent of the globe. He has over

the last fifteen years built strong working collaborations with reputable research groups in numerous and leading Universities across the globe. He is the convener for Recent Advances in Biotechnology, which is an annual international conference where renowned microbiologists and biotechnologists co

me together to share their latest discoveries. He is also the Founder & CEO of BECTIK Biotechnology and Nanotechnology Company.

探討CPT1C在類基底型乳癌中調控上皮-間質轉型及腫瘤幹細胞特性所扮演的角色

為了解決A marker的問題，作者王慶弘 這樣論述：

代謝途徑重整是腫瘤的重要特徵之一，腫瘤細胞可藉由調控自身的代謝偏好而有利其在代謝壓力的情況下存活，並維持高速增生。有研究更進一步指出乳癌細胞傾向於透過調控脂肪酸氧化代謝的效率限制酶CPT1C來增加脂肪酸氧化的活性，進而促進細胞增生，甚至維持腫瘤幹細胞特性及產生抗藥性。因此，本研究旨在釐清類基底型乳癌是否透過調節CPT1C影響細胞脂肪酸氧化代謝的活性，進而誘發上皮-間質細胞轉型及腫瘤幹細胞特性。我們的先導結果指出，透過TCGA數據資料庫分析，CPT1C表現量在類基底型乳癌患者中高於其他乳癌類型，並在具有淋巴結轉移或遠端轉移的患者中具有較高的表現量;而在類基底型乳癌患者中，擁有較高CPT1C表現

量的族群同時存活率也較差。此外，在類基底型乳癌患者中，相較於其他CPT1同功酶(CPT1A、CPT1B)， 唯有CPT1C的表現量和存活率呈現負相關。接著，正常類基底型人類乳腺上皮細胞中過度表現CPT1C會增加脂肪酸氧化代謝活性，同時也誘導上皮-間質細胞轉型、細胞遷移、侵襲，並且提升腫瘤幹細胞特性；反之，利用微小干擾RNA抑制類基底型乳癌細胞株的CPT1C表現則可降低腫瘤的發展。以上結果顯示CPT1C確實在類基底型乳癌細胞的高度上皮-間質細胞轉型及癌幹性中扮演不可或缺的角色，未來我將繼續探討調控CPT1C的分子機制及利用動物實驗進行驗證。我們的研究不僅對於新穎療法的開發有很大的幫助，也釐清現行

生酮飲食療法用於類基底型乳癌的謬誤。關鍵詞: 脂肪酸氧化、CPT1C、類基底型乳癌、上皮-間質細胞轉型、腫瘤幹細胞特性